New class of cancer drugs could work in colon cancers with genetic mutation, study finds

April 25, 2011 in Cancer

New class of cancer drugs could work in colon cancers with genetic mutation, U-M study finds

Enlarge

Cells with mutations in the MRE11 gene do not detect DNA damage induced after radiation. The left image represents the normal gene, the middle image represents one copy of the mutated gene, and right image represents two copies of the mutated gene. Credit: University of Michigan Health System

A class of drugs that shows promise in breast and ovarian cancers with BRCA gene mutations could potentially benefit colorectal cancer patients with a different genetic mutation, a new study from the University of Michigan Comprehensive Cancer Center finds.

Working in cell lines from colorectal cancer patients, researchers found that a new class of drugs called PARP inhibitors worked against tumors with mutations in the MRE11 gene.

About 15 percent of all colorectal cancers have what's called microsatellite instability, a type of error in the DNA. About 82 percent of those tumors have the MRE11 .

"This is a potential broader application for PARP inhibitors, beyond breast and . This is a class of drug that's already shown safety in early and now might benefit some colorectal cancer patients as well," says lead study author Eduardo Vilar-Sanchez, M.D., Ph.D., a /oncology fellow at the U-M Medical School.

The study, which was published in Cancer Research, also found that PARP inhibitors are even more effective when both copies of MRE11 were mutated. Each person carries two copies of each gene, which means mutations can occur in either one or both copies. The researchers suggest that PARP inhibitors could be targeted specifically to colorectal cancer patients who have two copies of the mutated gene.

Researchers are planning a phase I clinical trial to look at using PARP inhibitors in colorectal cancer patients with two mutated copies of MRE11. Future trials are being considered using PARP inhibitors to prevent colorectal cancer and other cancers in people with Lynch syndrome whose tumors have this mutation.

Microsatellite instability is also seen in and endometrial cancer, suggesting potential for PARP inhibitors to play a role in additional types of as well, Vilar-Sanchez says, adding that more research is needed in these areas.

More information: Cancer Research, Vol. 71, No. 7, April 1, 2011

Provided by University of Michigan Health System search and more info website

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

Key find for early bladder cancer treatment

Aggressive forms of bladder cancer involve the protein PODXL – a discovery that could hold the key to improved treatment, according to researchers at Lund University, Uppsala University and KTH in Sweden.

Cancer created 17 minutes ago | popularity 5 / 5 (1) | comments 0

Cold plasma successful against brain cancer cells

For the first time, physicists from the Max Planck Institute for Extraterrestrial Physics (MPE), biologists and physicians demonstrated the synergistic effect of cold atmospheric plasma - a partly ionized ...

Cancer created 47 minutes ago | popularity 5 / 5 (1) | comments 0 | with audio podcast

Non-Hodgkin lymphoma survival doubles since early 1970s

More than half of patients diagnosed with Non-Hodgkin Lymphoma (NHL) are now surviving the disease thanks to improved diagnosis and treatment, according to a new report1 from Cancer Research UK.

Cancer created 1 hour ago | popularity 5 / 5 (1) | comments 0

Researchers find possible 'master switch' in deadly brain cancer

(Medical Xpress)—Researchers at the University of Virginia School of Medicine have identified a promising target for treating glioblastoma, one that appears to avoid many of the obstacles that typically frustrate efforts ...

Cancer created 1 hour ago | popularity 5 / 5 (1) | comments 0 | with audio podcast

American cancer society celebrates 100 years of progress

(HealthDay)—The American Cancer Society, which is celebrating on Wednesday a century of fighting a disease once viewed as a death sentence, is making a pledge to put itself out of business.

Cancer created 15 hours ago | popularity not rated yet | comments 0


Can you put a price on health?

As health services strive to improve quality and reduce costs, researchers study the benefits – and the pitfalls – of 'pay for performance' in hospitals.

Study reveals active site of enzyme linked to stuttering

(Medical Xpress)—Scientists from the Joint Center for Structural Genomics (JCSG) at SLAC National Accelerator Laboratory have determined the 3-D structure of the chemically active part of an enzyme involved ...

Are kids who take music lessons different from other kids?

(Medical Xpress)—Research by U of T Mississauga psychology professor Glenn Schellenberg reveals that two key personality traits – openness-to-experience and conscientiousness—predict better than IQ ...

Researchers develop sperm-sorting design that may aid couples undergoing in vitro fertilization

(Medical Xpress)—According to the World Health Organization, approximately 70 million couples experience infertility worldwide. Current data suggests that nearly one third of infertility disorders are due ...

Common brain processes of anesthetic-induced unconsciousness identified

A study from the June issue of Anesthesiology found feedback from the front region of the brain is a crucial building block for consciousness and that its disruption is associated with unconsciousness when the anesthetics ketami ...

Parents can help preteens with abduction concerns

Parents naturally are concerned for their children's safety, particularly when there is news of a child abduction that happens close to home. Finding the balance between emotions and the "teachable moment" as parents talk ...